Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Conditions

• Melanoma and Other Malignant Neoplasms of Skin
• Metastatic Melanoma

Interventions

• DRUG: GSK2636771
• DRUG: Pembrolizumab

Sponsor

M.D. Anderson Cancer Center

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]